Related references
Note: Only part of the references are listed.Effects of Sonidegib Following Dose Reduction and Treatment Interruption in Patients with Advanced Basal Cell Carcinoma During 42-Month BOLT Trial
Karl Lewis et al.
DERMATOLOGY AND THERAPY (2021)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Alexander J. Stratigos et al.
LANCET ONCOLOGY (2021)
Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
Alon Kahana et al.
ONCOLOGIST (2021)
Itraconazole in the treatment of basal cell carcinoma: A case-based review of the literature
Ken Hiu-Kan Ip et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2021)
Complete Remission of Basal Cell Carcinoma Following Treatment With Cemiplimab After 2 Years
Konstantin Dumann et al.
JAMA DERMATOLOGY (2021)
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study) Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma
Nicolas Bertrand et al.
ECLINICALMEDICINE (2021)
Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study
R. Dummer et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Adherence to the National Comprehensive Cancer Network Criteria of Complete Circumferential Peripheral and Deep Margin Assessment in Treatment of High-Risk Basal and Squamous Cell Carcinoma
Melissa J. Danesh et al.
DERMATOLOGIC SURGERY (2020)
Basal cell carcinoma Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations
Michael C. Cameron et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study
Anne Lynn S. Chang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
Yunlong Zhao et al.
IMMUNITY (2019)
Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis
Pingxing Xie et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Guidelines of care for the management of basal cell carcinoma
Christopher Bichakjian et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials
Ricardo Costa et al.
ONCOTARGET (2017)
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N. Basset-Seguin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities
Julia Chang et al.
JAMA DERMATOLOGY (2017)
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
Guillermo De Velasco et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic et al.
BMC CANCER (2017)
Radiotherapy in Gorlin Syndrome: Can It Be Safe and Effective in Adult Patients?
Sarah Baker et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in a large commercially insured population in the United States: A retrospective cohort study
Gary Goldenberg et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma A Systematic Review and Pooled Analysis of Interventional Studies
Audrey A. Jacobsen et al.
JAMA DERMATOLOGY (2016)
Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus
Ketty Peris et al.
FUTURE ONCOLOGY (2015)
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
Jason J. Luke et al.
ONCOTARGET (2015)
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma
Sabrina Pricl et al.
MOLECULAR ONCOLOGY (2015)
Defining and recognising locally advanced basal cell carcinoma
Jean Michel Amici et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2015)
Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective
J. T. Lear et al.
BRITISH JOURNAL OF CANCER (2014)
Basal cell carcinomas in a tertiary referral centre: a systematic analysis
J. Dreier et al.
BRITISH JOURNAL OF DERMATOLOGY (2014)
Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up
Eva van Loo et al.
EUROPEAN JOURNAL OF CANCER (2014)
Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma
Daniel J. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates
Changyu Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Itraconazole and Arsenic Trioxide Inhibit Hedgehog Pathway Activation and Tumor Growth Associated with Acquired Resistance to Smoothened Antagonists
James Kim et al.
CANCER CELL (2013)
Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
Anne Lynn S. Chang et al.
ARCHIVES OF DERMATOLOGY (2012)
PERINEURAL INFILTRATION OF CUTANEOUS SQUAMOUS CELL CARCINOMA AND BASAL CELL CARCINOMA WITHOUT CLINICAL FEATURES
Charles Lin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Superficial x-ray in the treatment of basal and squamous cell carcinomas: A viable option in select patients
Armand B. Cognetta et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Basal cell carcinomas: attack of the hedgehog
Ervin H. Epstein
NATURE REVIEWS CANCER (2008)
Radiotherapy for malignancy in patients with scleroderma: The Mayo Clinic experience
Douglas G. Gold et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Influence of connective tissue diseases on the expression of radiation side effects:: A systematic review
T Hölscher et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas
KW Schulte et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Nevoid basal cell carcinoma syndrome associated with unilateral renal agenesis: acceleration of basal cell carcinomas following radiotherapy
A Bacanli et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2005)
Craniofacial resection for nonmelanoma skin cancer of the head and neck
DD Backous et al.
LARYNGOSCOPE (2005)
Radiotherapy for locally advanced basal cell and squamous cell carcinomas of the skin
W Kwan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Superficial radiotherapy for patients with basal cell carcinoma -: Recurrence rates, histologic subtypes, and expression of p53 and Bcl-2
B Zagrodnik et al.
CANCER (2003)
Radiotherapy for epithelial skin cancer
J Locke et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage
MOF Al-Othman et al.
AMERICAN JOURNAL OF OTOLARYNGOLOGY (2001)
Share Paper
